Galderma Group AG

Galderma’s latest ASDS data show Restylane, Sculptra and Relfydess deliver strong, lasting volume with minimal side‑effects—evidence that could shape future aesthetic practice.

Galderma’s 2.6 billion‑CHF share sale fuels R&D, market expansion, and strategic M&A while keeping stock above the offer price, showcasing strong investor confidence and growth potential in dermatology and aesthetic medicine.

Galderma Group AG, a specialist in dermatological therapeutics, has reported a modest share price uptick, driven by solid fundamentals and a diversified pricing strategy, but faces patent expiration risks and must navigate market constraints to sust…

Galderma’s stock price is under scrutiny due to its high valuation and volatility, leaving investors wondering if it’s a sustainable price or a bubble waiting to burst.

Galderma’s share price has stabilized following the EQT sale, with a 52-week high of 138.8 CHF and a price to earnings ratio of 98.48, indicating potential for long-term growth.

Galderma Group AG’s stock price plummeted 8% after EQT sold 17 million shares, resulting in a significant impact on the company’s market capitalization.

Galderma, a leading dermatological treatments and skin care company, achieved a record-breaking 12.2% year-on-year sales growth in the first half of 2025, driven by strong performance from its Cetaphil brand.

Galderma, a Switzerland-based dermatological company, has smashed sales records with a 12.2% year-on-year increase in the first half of 2025, driven by the success of its Cetaphil brand.

Galderma Group AG’s stock price has declined due to market volatility, but the company’s long-term prospects remain strong due to its commitment to innovative dermatological solutions.

Galderma’s first-half performance has shattered records, driven by double-digit growth in international markets and a diversified product portfolio, solidifying its position as a leader in the dermatology space.